Taiwan Biotech
Taiwan 36 employees Updated 9 July 2026
Taiwan Biotech is an API manufacturer based in Taiwan. It holds one active US drug master file and one valid CEP. Its filings concentrate with DAV (Vietnam), NPRA (MY) and MINSA (CR). Its most recent recorded inspection, by US FDA, closed on 20 September 2022 as OAI.
2
registered plants
1 with an FDA FEI number
34
filings
across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 20 September 2022 OAI US FDA
- 11 September 2017 OAI US FDA
- 30 May 2014 VAI US FDA
- 26 August 2011 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Taoyuan City, Taiwan | Not on file |
| Taiwan, Taiwan | 3003598505 |
What they file, and where
| Molecule | Regulators | Docs |
| Bisoprolol | EDQM, US FDA | 2 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| DAV (Vietnam) | 19 | None |
| NPRA (MY) | 10 | None |
| MINSA (CR) | 3 | None |
| NMPA (CN) | 2 | None |
Comparing suppliers?
Choose your molecules and target markets. Taiwan Biotech comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was OAI, on 20 September 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability